<?xml version='1.0' encoding='utf-8'?>
<document id="25418605"><sentence text="Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam."><entity charOffset="50-59" id="DDI-PubMed.25418605.s1.e0" text="nilotinib" /></sentence><sentence text="Effects of single and repeated doses of nilotinib on the pharmacokinetics of midazolam, a cytochrome P450 3A (CYP3A) substrate, were assessed in 2 separate studies"><entity charOffset="40-49" id="DDI-PubMed.25418605.s2.e0" text="nilotinib" /><entity charOffset="77-86" id="DDI-PubMed.25418605.s2.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.25418605.s2.e0" e2="DDI-PubMed.25418605.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25418605.s2.e0" e2="DDI-PubMed.25418605.s2.e1" /></sentence><sentence text=" In the single-dose nilotinib study, 18 healthy subjects were randomized to 6 treatment sequences to receive single dose of nilotinib 600 mg, midazolam 4 mg, and coadministration of both in a crossover manner"><entity charOffset="20-29" id="DDI-PubMed.25418605.s3.e0" text="nilotinib" /><entity charOffset="124-133" id="DDI-PubMed.25418605.s3.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.25418605.s3.e0" e2="DDI-PubMed.25418605.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25418605.s3.e0" e2="DDI-PubMed.25418605.s3.e1" /></sentence><sentence text=" In the repeated-dose nilotinib study, 19 chronic myeloid leukemia patients took a single dose of midazolam 2 mg on days 1 and 13, and nilotinib 400 mg twice daily from days 2-13"><entity charOffset="22-31" id="DDI-PubMed.25418605.s4.e0" text="nilotinib" /><entity charOffset="98-107" id="DDI-PubMed.25418605.s4.e1" text="midazolam" /><entity charOffset="135-144" id="DDI-PubMed.25418605.s4.e2" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.25418605.s4.e0" e2="DDI-PubMed.25418605.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25418605.s4.e0" e2="DDI-PubMed.25418605.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25418605.s4.e0" e2="DDI-PubMed.25418605.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25418605.s4.e1" e2="DDI-PubMed.25418605.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25418605.s4.e1" e2="DDI-PubMed.25418605.s4.e2" /></sentence><sentence text=" In the single-dose study, the geometric mean ratio of the area under the plasma concentration time curve extrapolated to infinity (AUC(inf)) of midazolam plus nilotinib vs" /><sentence text=" midazolam was 1"><entity charOffset="1-10" id="DDI-PubMed.25418605.s6.e0" text="midazolam" /></sentence><sentence text="3 (90%CI, 1" /><sentence text="2-1" /><sentence text="5) and the maximum observed serum concentration (C(max)) was 1" /><sentence text="2 (90%CI, 1" /><sentence text="0-1" /><sentence text="4)" /><sentence text=" In the repeated-dose study, the values for AUC(inf) and C(max) were 2" /><sentence text="6 (90%CI, 2" /><sentence text="1-3" /><sentence text="3) and 2" /><sentence text="0 (90%CI, 1" /><sentence text="7-2" /><sentence text="4), respectively" /><sentence text=" These results indicate that single-dose and repeated-dose administration of nilotinib results in weak and moderate inhibition of CYP3A, respectively"><entity charOffset="77-86" id="DDI-PubMed.25418605.s20.e0" text="nilotinib" /></sentence><sentence text=" Therefore, appropriate monitoring and dose adjustment may be needed for drugs that are mainly metabolized by CYP3A, and have narrow therapeutic index, when coadministered with nilotinib"><entity charOffset="177-186" id="DDI-PubMed.25418605.s21.e0" text="nilotinib" /></sentence><sentence text="" /></document>